MCA
VKTX icon

Magnolia Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Magnolia Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Hold
12,115
– – 0.08% 204
2026
Q1 		$394K Sell
12,115
-2
-0% -$64 0.08% 226
2025
Q4 		$426K Buy
12,117
+250
+2% +$8.86K 0.09% 195
2025
Q3 		$312K Sell
11,867
-1
-0% -$30 0.08% 190
2025
Q2 		$315K Buy
11,868
+3
+0% +$79 0.08% 197
2025
Q1 		$287K Buy
11,865
+810
+7% +$25.6K 0.08% 194
2024
Q4 		$445K Buy
+11,055
New +$630K 0.12% 164

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Magnolia Capital Advisors's VKTX Position: Q2 2026 in Review

Magnolia Capital Advisors held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 12,115 shares worth $473K. The position accounts for 0.08% of the portfolio, ranked #204.

Magnolia Capital Advisors first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Magnolia Capital Advisors held 12,115 shares of Viking Therapeutics worth $473K as of Q2 2026.
  • Magnolia Capital Advisors left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.08% of Magnolia Capital Advisors's portfolio in Q2 2026, its #204 holding.
  • Magnolia Capital Advisors first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Magnolia Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.